[Initial results in the treatment of male fertility disorders with kallikrein: asthenozoospermia].
30 patients with asthenozoospermia were treated with kallikrein a kinin-liberating proteinase over a period of seven weeks. During parenteral and oral application of kalikrein and after medication within an observation period of 3 months a significant increase of the quantitative and qualitative sperm motility was found. Parenteral application of kallikrein led to a significant increase of the number of spermatozoa 3 months after beginning of the kallikrein therapy. Other semen parameters were not influenced. No side-effects were observed.
D000284:Administration, Oral; D006801:Humans; D007248:Infertility, Male / Q000188:drug therapy*; D007610:Kallikreins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D013081:Sperm Motility / Q000187:drug effects; D013094:Spermatozoa / Q000187:drug effects
D007610:Kallikreins
Erste Ergebnisse der Behandlung von männlichen Fertilitätsstörungen mit Kallikrein: Asthenozoospermie